Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis Bio Inc. (NYSE American:ANVS) announced its participation in the LD 500 investor conference on September 1, 2020, at 9:20 AM EDT. CEO Maria Maccecchini will present the company’s innovative approach to treating Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. The company is currently conducting two Phase 2 trials focused on these conditions. The LD 500, running from September 1-4, will be virtual, making it accessible to all interested parties. For more information, visit annovisbio.com.
Annovis Bio Inc. (NYSE American: ANVS) has resumed patient recruitment for its suspended Phase 2a clinical trial targeting Alzheimer’s disease (AD) and initiated a new Phase 2a trial for both AD and Parkinson’s disease (PD). The first trial involves 24 patients and is in collaboration with major institutions. Initial data is expected in early 2021. The second trial will also enroll patients across 15 US sites, with results anticipated in summer 2021. The company plans to report final data from long-term toxicology studies by fall 2020 to confirm the safety of its lead compound, ANVS401.
On July 23, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini will appear on Executive Leaders Radio on July 26, 2020. The show focuses on interviews with prominent CEOs, particularly within life sciences, discussing professional success and personal stories. Dr. Maccecchini expressed her enthusiasm for sharing the Annovis story and her personal commitment to neurodegeneration solutions. Annovis Bio, based in Berwyn, PA, is focused on developing drugs for Alzheimer’s and Parkinson’s diseases, with ongoing Phase 2a studies targeting these conditions.
Annovis Bio (NYSE American: ANVS) announces that CEO Maria Maccecchini, Ph.D., will present at the University of Pennsylvania on July 20, 2020. Her talk, titled “Rethinking Parkinson’s Disease”, addresses a novel treatment approach for Parkinson's disease at the Parkinson’s Disease and Movement Disorders Center, recognized as a global Center of Excellence.
Maccecchini will discuss the toxic cascade caused by neurotoxic proteins in neurodegenerative diseases, presenting data from clinical trials using ANVS401, Annovis Bio's lead compound.
Annovis Bio (ANVS) has received Central IRB approval to initiate a Phase 2 clinical study targeting early Parkinson's disease (PD) and Alzheimer's disease (AD) patients. The study will involve 68 patients over four weeks, assessing the lead compound, ANVS401, for its effects on nerve cell death and cognitive functions. The trial aims to understand safety, tolerability, and the potential reversal of toxic cascades affecting nerve cells. CEO Maria Maccecchini expressed optimism about staying on schedule to complete the study by Q1 2021, despite initial delays related to COVID-19.
Annovis Bio Inc. (NYSE American: ANVS) announced the successful completion of a chronic toxicology study for its lead compound, ANVS401, with no adverse side effects reported in rats. Funded by a $1.7 million NIH grant, this six-month study corroborates previous positive results from shorter studies. CEO Maria Maccecchini highlighted this milestone as critical for advancing long-term human studies. Ongoing safety studies on dogs are anticipated to yield results in Q3 2020, supporting Annovis's ongoing clinical trials for Alzheimer's and Parkinson's diseases.
On June 9, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced that its CEO, Maria Maccecchini, Ph.D., and CFO, Jeff McGroarty, MBA, CPA, will present virtually at the June 2020 Virtual Summer Investor Summit from June 9-12, 2020. The presentation is scheduled for June 10 at 10:55 a.m. ET, followed by a live Q&A session. Annovis Bio focuses on developing treatments for Alzheimer’s and Parkinson’s diseases, with ongoing clinical studies to improve neurodegeneration. Investors can register for the summit and access the live webcast online.
On June 2, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced that the European Patent Office granted a patent for a method to treat Alzheimer's disease with its lead compound, ANVS401. This patent complements the existing US patent for Parkinson's Disease. CEO Maria Maccecchini highlighted plans for additional patents targeting various neurodegenerative diseases. Annovis Bio is conducting two Phase 2 studies of ANVS401 to demonstrate its efficacy in preserving nerve cell function in Alzheimer's and Parkinson's patients.
Annovis Bio (NYSE American: ANVS) announced that its 2020 Annual Meeting of Stockholders will be held virtually on June 3, 2020, at 10:00 a.m. ET. Shareholders are encouraged to attend and vote using their Virtual Control Number. The Notice of Annual Meeting, Proxy Statement, and Annual Report for the year ended December 31, 2019, are accessible online. The company is focused on developing treatments for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, with ongoing clinical trials aimed at improving patient outcomes.
Summary not available.